CCBM, while I do agree that making inroads takes a while I must also point out that this is why the partnering agreement pending will tell us a lot more, I have stated this in previous posts also. If we sign with an International Wound Healing company that already has great inroads and large distribution channels I doubt that "The real returns will take many years to develop" as you state, but one can never rule it out.
I personally tick off LT Buy as I know this sector can take time, longer than first thought by many, my figures are for best outcome style projection and are loosely based on assumption, I make no bones about it and pepper my posts with that sentiment.
As far as gaining market share I think some of Prof Keith Harding's comments can give a great insight as to how well endorsed VitroGro could be by himself, the patients and the International Wound Healing partner we attract, all to replace the current standard of care:
Q: So what is your perspective on the early VitroGro trials?
Keith Harding: I have been around this subject for nearly 30 years. I have seen a lot of new products come and go. The one thing that was impressive both from the preclinical data and the early clinical studies is that in the clinical studies particularly, there seemed to be a greater consistency of response in the patients that were exposed to this product, far more consistent than I?ve seen with other biological therapies that I personally have been involved in trialling or evidence that I have reviewed in other capacities.
Q: What do you think the potential for VitroGro is if trials continue to support the early evidence?
Keith Harding: The potential for VitroGro if the evidence that emerges supports the data that is already there is enormous. In many parts of the world many patients with wounds are still treated with very simple basic therapies. It is increasingly recognized that there are many aberrations in that healing process that can occur in a wide range of wound types that are based in abnormalities in the biological response to injury. If VitroGro can correct that abnormality, the potential for replacing a lot of the basic treatment or working in combination with basic treatment to get better clinical results is enormous and I think it is much more important to recognize although there is benefit for Tissue Therapies as an organization, I am confident there will be many patients who will benefit from this biologically based therapy which will hopefully continue to show the promising results we?ve seen in early clinical studies.
I'm not too sure what your getting at with your link you provided as they seem to be very early stage and concentrating on burns atm, another technology yes, but?:
"Over the counter, spray-on stem cell treatment could heal burns on the go By Laura June posted Dec 2nd 2010 1:54PM Research at the University of Utah could lead to burn treatment on the go that makes use of your body's own cells. Surgeons Amit Patel and Amalia Cochran are researching the use of stem cells in conjunction with several chemicals as a spray-on jelly which has, in early testing, shown to accelerate the healing process of burns. While the team is starting with small burns, its goal is to be able to provide fast and effective, actual regeneration of a patient's own cells to be grafted onto large area burns"
Anyway we will get to see soon enough if the partnering deal is significant, by then speculating on how long it is going to take could lead to missed re-ratings of the stock. I found this link.....
.....rather interesting with regards to diabetics and foot ulcers, as of 2007, 4 million people with diabetes will develop a foot ulcer every year. The costs are dramatic to individual countries and their healthcare systems and the authorities want a lower cost solution, as I said in my post your responding to, if you don't agree then halve it:))
TIS Price at posting:
47.9¢ Sentiment: LT Buy Disclosure: Held